In in vivo models of JAK dependent malignancy, itacitinib impedes subcutaneous tumor growth of INA-6 cells expressing wild type JAKs when administered by continuous infusion, achieving plasma concentrations well below those necessary to inhibit JAK2. Here, JAK2 is linked to neoplasm.